PP
Therapeutic Areas
CytoSorbents Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CytoSorb® / CytoSorb 300® | Reduction of elevated cytokines, bilirubin, myoglobin | Commercial (CE Mark) |
| DrugSorb-ATR® | Removal of Ticagrelor/Rivaroxaban during cardio-pulmonary bypass surgery | Commercial (CE Mark) / Pivotal Trial (US) |
| ECOS-300CY® | Inflammatory mediator reduction during ex vivo organ perfusion | Investigational / Early Commercial |
| VetResQ® | Veterinary critical care (sepsis, pancreatitis, etc.) | Commercial |
| PuriFi® | Enabling device for independent CytoSorb® therapy | Commercial (CE Mark) |
Leadership Team at CytoSorbents
EN
Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI
Chief Medical Officer
PJ
Peter J. Mariani
Chief Financial Officer
DW
Daniel Wendt, FECTS, FACS, MHBA
Vice President Medical Cardio-Vascular
HA
Harriet Adamson
Senior Manager Medical Information
DJ
Dr. Jörg Scheier
Vice President Medical Critical Care